Insights

In-depth interviews with decision-makers, stakeholders, and researchers on timely and emerging trends in clinical data, health policy, value-based care, and more!

June 22nd 2022Managing Mutations in Non-Small Cell Lung Cancer

Three experts discuss advanced non-small cell lung cancer and what it means to have a treat a KRAS G12C mutation.

June 13th 2022The Role and Value of Prescription Digital Therapeutics in Behavioral Disorders

Two experts, one provider and one payer, shed light on their experiences with prescription digital therapeutics within the behavioral care landscape.

$IMiDs in Relapsed/Refractory Multiple Myeloma$

June 6th 2022IMiDs in Relapsed/Refractory Multiple Myeloma

Two experts discuss the role immunomodulatory drugs (IMiDs) play in the current treatment landscape for relapsed/refractory multiple myeloma and how they can be used effectively.

April 8th 2022Mitigating Cardiovascular Risk Through Effective Lipid Management

Ian Riddock, MD, and Eliot Brinton, MD, discuss effective use of lipid lowering therapies in patients with atherosclerotic cardiovascular disease (ASCVD).

December 20th 2021Cardiovascular Risk and Prostate Cancer Management

Shared insight on the role cardiovascular disease management plays in the prostate cancer treatment paradigm.

October 26th 2021Optimizing the Transition to Biosimilars: Considerations for Payers

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.

August 13th 2021Management of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

X. Long Zheng, MD, PhD, gives an overview of acquired thrombotic thrombocytopenic purpura and the treatment considerations for the disease.

August 5th 2021AJMC Insights: Lupus Nephritis

Rheumatologist Ellen Ginzler, MD, MPH, and nephrologist German Hernandez, MD, FASN, FACP, explore the current treatment landscape of lupus nephritis and the managed care considerations of recent FDA approved therapies for the disease.

January 26th 2021Heart Failure With Preserved Ejection Fraction: Current Status and Future Opportunities

Key opinion leaders discuss the key differences and unmet needs in disease management for heart failure with preserved ejection fraction and heart failure with reduction ejection fraction.

January 25th 2021CAR T-Cell Therapy for the Management of Multiple Myeloma

Oncologists explore the opportunity of CAR T-cell therapy for the treatment of relapsed/refractory multiple myeloma.

January 18th 2021New Directions in Chemotherapy-Induced Neutropenia

A clinician and payer discuss the impact of chemotherapy-induced neutropenia on patients as well as the healthcare system, and discuss the latest in prophylactic treatment, especially during the COVID-19 pandemic.